EnteroMedics acquired ReShape Medical and its ReShape Dual Weight Loss Balloon, a minimally invasive intragastric balloon system.
Here's what you should know:
1. ReShape designed the intragastric balloon system to treat obese patients with a body mass index between 30 or 40 and a related comorbid condition.
2. EnteroMedics is acquiring 2,356,729 shares of common stock, 187,772 shares of series C convertible preferred stock and $5 million in cash.
3. EnteroMedics will hold a stockholder meeting on Dec. 31 to approve the conversion of the series C stock into common stock.
4. EnteroMedics CEO and President Dan Gladney will stay in his current position. ReShape Medical will add two designees to Entero's board of directors.